Presentation will be available on demand as part of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting BOSTON, MA and WILMINGTON, DE / ACCESSWIRE / June 4, 2021 / MorphoSys US Inc.,
DGAP-News: MorphoSys AG / Key word(s): Miscellaneous04.06.2021 / 19:32 The issuer is solely responsible for the content of this announcement.Media ReleaseMorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refract.
Edmonton, Alberta and Austin, Texas (Newsfile Corp. - June 2, 2021) - To view the full announcement, including downloadable images, bios, and more, click here. Key Takeaways: Clinical site preparations
Gilead-Kite Oncology demonstrate dedication to advancing research for hard-to-treat blood cancers at 26th Annual Meeting of the European Hematology Association (EHA) Primary results of pivotal ZUMA-3 trial, including pre-specified patient reported outcomes (PRO) in adult patients with relapsed/refractory acute lymph.
Oncopeptides presents new clinical and preclinical melflufen data at the upcoming European Hematology Association meeting
STOCKHOLM, May 12, 2021 /PRNewswire/ Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announces that new clinical and preclinical data have been accepted by the European Hematology Association, EHA, and been published online. The clinical data presentation contains interim results from the phase 2 BRIDGE study supporting the use of melflufen in relapsed refractory multiple myeloma patients with moderately impaired renal function. Two preclinical data presentations show the future potential of melflufen in treatments of other hematological diseases outside multiple myeloma. In addition, the last preclinical data presentation provides an increased understanding of melflufen s mode of action.